What evidence shows in the approach of T2D – Dr. Manuel Cigarruista

Dr. Manuel Cigarruista, an endocrinologist from Panama, states that early and strict control of HbA1c is the 1st objective in the management of patients with T2D, since it is directly related to long-term cardiovascular and renal protection. To achieve this control, it is necessary to use treatments such as Gliclazide MR which not only offers the best reduction of HbA1c compared to different oral antidiabetic treatments, but also provides important macro and microvascular protection.

SCAC 03/22 DM 039 DIA